Skip to main content


1. Bilimoria KY, Bentrem DJ, Ko CY, et al: Validation of the 6th edition AJCC Pancreatic Cancer Staging
System: report from the National Cancer Database. Cancer 110:738-744, 2007
2. Park JK, Yoon YB, Kim YT, et al: Survival and prognostic factors of unresectable pancreatic cancer.
J Clin Gastroenterol 42:86-91, 2008
3. Feldmann G, Beaty R, Hruban RH, Maitra A.: Molecular genetics of pancreatic intraepithelial neoplasia.
J Hepatobiliary Pancreat Surg 14:224-232, 2007
4. Izeradjene K, Combs C, Best M, et al: Kras(G12D) and Smad4/Dpc4 haploisufficiency cooperate to
induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell
11:229-242, 2007
468 Gastro Update 2008
5. Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 197:1901-1908, 2007
6. Chen Y, Zheng B, Robbins DH, et al: Accurate discrimination of pancreatic ductal adenocarcinoma and
chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive
fine needle aspiration. Int J Cancer 120:1511-1517, 2007
7. Chang MC, Chang YT, Su TC, et al: Adiponectin as a potential differential marker to distinguish pancreatic
cancer and chronic pancreatitis. Pancreas 35:16-21, 2007
8. di Magliano MP, Biankin AV, Heiser PW, et al: Common activation of canonical Wnt signalling in
pancreatic adenocarcinoma. PLoS ONE 11:01155, 2007
9. Tzeng CW, Frolov A, Frolova N, et al: EGFR genomic gain and aberrant pathway signalling in pancreatic
cancer patients. J Surg Res 143:20-26, 2007
10. Tzeng CW, Frolov A, Frolova N, et al: Pancreatic cancer epidermal growth factor receptor (EGFR)
intron 1 polymorphism influences postoperative patients survival and in vitro erlotinib response. Ann
Surg Oncol 14:2150-2158, 2007
11. Dancer J, Takei H, Ro JY, Lowery-Nordberg M.: Coexpression of EGFR and HER-2 in pancreatic ductal
adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification
by fluorescencent in situ hybridization. Oncol Rep 18:151-155, 2007
12. Mitsunaga S, Hasebe T, Kinoshita T, et al: Detail histologic analysis of nerve plexus invasion in invasive
ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol 31:1636-1644, 2007
13. Loukopoulos P, Shibata T, Katoh H, et al: Genome-wide array-based comparative genomic hybridization
analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome.
Cancer Sci 98:392-400, 2007
14. Cho K, Ishiwata T, Uchida E, et al: Enhanced expression of keratinocyte growth factor and its receptor
correlates with venous invasion in pancreatic cancer. Am J Pathol 170:1964-1974, 2007
15. Torer N, Kayaselcuk F, Nursal TZ, et al: Adhesion molecules as prognostic markers in pancreatic
adenocarcinoma. J Surg Oncol 96:419-423, 2007
16. Ohuchida K, Mizumoto K, Miyasaka Y, et al: Over-expression of S100A2 in pancreatic cancer correlates
with progression and poor prognosis. J Pathol 213:275-282, 2007
17. Bister V, Skoog T, Virolainen S, et al: Increased expression of matrix metalloproteinases-21 and -26 and
TIMP-4 in pancreatic adenocarcinoma. Mod Pathol 20:1128-1140, 2007
18. Sasada T, Azuma K, Hirai T, et al: Prognostic significance of the immediate early response gene X-1
(IEX-1) expression in pancreatic cancer. Ann Surg Oncol 2007
19. Weichert W, Boehm M, Gekeler V, et al: High expression of RelA/p65 is associated with activation of
nuclear factor-kB-dependent signalling in pancreatic cancer and marks a patient population with poor
prognosis. Br J Cancer 97:523-530, 2007
20. Maeda S, Shinchi H, Kurahara H, et al: Clinical significance of midkine expression in pancreatic head
carcinoma. Br J Cancer 97:405-411, 2007
21. Lyshchik A, Higashi T, Hara T, et al: Expression of glucose transporter-1, hexokinase-II, proliferating
cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest 25:154-162, 2007
22. Tingstedt B, Johansson P, Andersson B, Andersson R.: Predictive factors in pancreatic ductal adenocarcinoma:
role of the inflammatory response. Scand J Gastroenterol 42:754-759, 2007
23. Nakachi K, Furuse J, Ishii H, et al: Prognostic factors in patients with gemcitabine-refractory pancreatic
cancer. Jpn J Clin Oncol 37:114-120, 2007
A hasnyálmirigy 469
24. Cortesini R.: Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). JOP
8:697-703, 2007
25. Nakahira S, Nakamori S, Tsujie , et al: Involvement of ribonucleotide reductase M1 subunit overexpression
in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355-1363, 2007
26. Saif MW, Black G, Roy S, et al: Phase II study of capecitabine with concomitant radiotherapy for
patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J
13:247-256, 2007
27. Sebastiani V, Ricci F, Rubio-Viquiera B, et al: Immunohistochemical and genetic evaluation of deoxycytidine
kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Clin Cancer Res 12:2492-2497, 2006